News

Oerth Bio Publishes Landmark Study Demonstrating the First Application of PROTACs in Agriculture
Oerth Bio today announced the publication of a groundbreaking peer-reviewed study in Nature Communications Biology ( ...
BioWorld1mon
New PDE4 degradation inducers disclosed in Katalytic patent
Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...
Arvinas presents first-in-human data from ARV-102 trial
Arvinas (ARVN) presented data from the first-in-human clinical trial of ARV-102, the Company’s investigational PROteolysis TArgeting Chimera ...
BioWorld1mon
Shenzhen Zhongge Biotechnology describes new IRAK-4 degradation inducers
Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...
Insider Monkey3d
10 Stocks Under $10 that Will Triple
Arvinas, Inc. (NASDAQ:ARVN) develops treatments that break down disease-causing proteins using its PROTAC (Proteolysis Targeting Chimera) technology. The company’s main drugs target prostate ...
Pharmabiz1mon
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial
These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The trial met its primary endpoint in the ...